Watson’s Generic Lovenox Launches At Risk; Will Sanofi’s Authorized Generic Follow?
This article was originally published in The Pink Sheet Daily
Executive Summary
An appeals court lifted a preliminary injunction that blocked Amphastar and U.S. marketing partner Watson from selling their generic version of Sanofi’s blood thinner. Watson is to launch immediately in the U.S.